By Kolaleh Eskandanian
May 8, 2026
In the high-stakes world of medical innovation, the "valley of death" is not just a metaphor; it is a graveyard of potentially life-saving technologies that failed to bridge the chasm between clinical validation and commercial viability. For years, the medical device industry has lobbied Washington for a singular, coherent path that marries regulatory approval with reimbursement. In late April, the Centers for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA) finally answered that call with the announcement of the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway.
On the surface, RAPID is a triumph of bureaucratic synergy. It promises a synchronized federal process that could grant Medicare national coverage as soon as two months after FDA market authorization—a staggering improvement over the current status quo, where families and manufacturers often languish for a year or more waiting for reimbursement decisions.
However, as someone who has spent over a decade guiding small companies through the grueling FDA review process, I find myself in a state of cautious optimism shadowed by deep systemic concern. While RAPID addresses a monumental hurdle for adult medicine, it fails to account for the unique, often ignored, struggles of pediatric and orphan device development. In fact, by focusing heavily on the traditional Medicare population, this new pathway may inadvertently widen the chasm between adult and pediatric innovation.
The Chronology of Coverage: A Broken System
To understand why RAPID is a significant, yet incomplete, development, one must look at the historical trajectory of medical device reimbursement.
For decades, the FDA and CMS operated in silos. A company could spend years securing FDA approval for a "Breakthrough" device, only to face a second, equally arduous "review" by CMS to determine if the device was "reasonable and necessary" for Medicare beneficiaries. This disjointed process created a period of financial limbo. Small startups, lacking the deep pockets of med-tech giants, often exhausted their capital during this waiting period, forcing many to shelve promising technologies or sell them to larger firms that might deprioritize them.
The Timeline of the Current Crisis:
- 2016–2020: The rise of the FDA’s Breakthrough Devices Program accelerates clinical pathways, but reimbursement lag remains unchanged.
- 2021–2023: Industry advocates and policy think tanks begin formalizing the "synchronization" argument, citing the "reimbursement gap" as the primary killer of innovation.
- April 2026: CMS and FDA issue the joint proposal for the RAPID coverage pathway, aiming to collapse the gap from 12+ months to 60 days.
While this timeline reflects a victory for administrative efficiency, the chronology ignores the unique biological and economic realities of pediatric patients. Children are not simply "small adults." Their medical needs require specialized equipment that rarely fits the traditional Medicare reimbursement model, which is fundamentally designed for geriatric care.
The Economics of Exclusion: Supporting Data
The core problem with the RAPID proposal is that it is built on the foundation of Medicare eligibility. Because Medicare is exclusively for the elderly and disabled, it does not apply to the pediatric population.
Current data from the Alliance for Pediatric Device Innovation (APDI) and other research bodies highlight a sobering reality:
- Market Disparity: Less than 10% of medical devices are specifically labeled for pediatric use.
- The "Orphan" Effect: Pediatric devices are often classified as "orphan" technologies—meaning they serve small populations. Because the market size is small, the investment return is low, making every day of reimbursement delay exponentially more damaging than it is for high-volume adult devices.
- The Funding Gap: While breakthrough adult devices receive billions in venture capital, pediatric innovation relies heavily on federal grants (like those from BARDA and the FDA’s PIs). When CMS-driven pathways like RAPID ignore the Medicaid-dependent pediatric population, they signal to investors that pediatric innovation remains a "charity case" rather than a viable market.
When we prioritize the speed of Medicare coverage without creating a parallel "Pediatric RAPID" pathway, we are essentially building a high-speed rail line that stops only at the retirement home, leaving the pediatric hospital off the map entirely.
Official Responses and the Policy Divide
The official stance from CMS and the FDA is that RAPID is the first step toward a broader, more efficient regulatory ecosystem. Officials argue that by proving the "synchronization model" works for the largest block of patients (Medicare beneficiaries), they create a blueprint that can eventually be scaled.
"Our goal is to reduce the administrative burden on innovators, allowing them to focus on what matters: patient care," a CMS spokesperson noted during the announcement. The FDA has similarly emphasized that this is a "cross-agency collaboration" designed to foster trust between regulatory and payor entities.
However, industry insiders are split. Large manufacturers, whose portfolios are heavily weighted toward cardiovascular and orthopedic devices for the elderly, have praised the move. Conversely, pediatric advocacy groups and small-cap innovators are sounding the alarm. The fear is that by "fixing" the adult pathway, regulators will feel they have checked the box on innovation reform, removing the political urgency needed to address the more complex, and admittedly more expensive, pediatric reimbursement landscape.
Implications: The Widening Gap
What are the implications for the future of pediatric health? If we continue to treat pediatric device innovation as an afterthought, we risk a "brain drain" in the sector.
- Talent Migration: If small companies are incentivized by faster pathways to build adult-only devices, the best minds in biomedical engineering will move away from developing pediatric-specific technologies.
- Stagnation of Care: We will continue to see a reliance on "off-label" use—where physicians use adult devices on children, often modifying them in ways that are technically unsafe but practically necessary. This is not how modern medicine should operate.
- The "Pediatric Penalty": As adult devices become cheaper and faster to bring to market under RAPID, the cost-to-benefit ratio of developing a pediatric device will look even worse to potential investors. The "Pediatric Penalty" will effectively increase, as pediatric innovation becomes more isolated from the mainstream, high-speed, and high-efficiency market.
A Call for a Parallel Path
I want the RAPID pathway to succeed. The medical community is desperate for the efficiency it promises. But for this to be a true success, it must be the start of a multi-tiered approach, not the end of the conversation.
We need a "Pediatric RAPID" equivalent. This would require:
- Medicaid Synchronization: A commitment from state and federal Medicaid programs to adopt the same expedited review timelines for FDA-cleared pediatric breakthrough devices.
- Dedicated Pediatric Review Boards: Just as the FDA has specialized review for pediatric devices, CMS needs a specific, empowered division that understands the value of pediatric life-cycle outcomes, rather than just short-term cost-savings.
- Incentive Alignment: Tax credits or extended patent exclusivity for companies that pursue pediatric-labeled devices, specifically to compensate for the market fragmentation that RAPID cannot solve on its own.
The announcement in April was a historic step toward modernizing our regulatory infrastructure. However, history will judge this administration not by how fast it gets devices to the elderly, but by whether it finally closes the gap for the most vulnerable among us. If the RAPID pathway remains a tool for adult medicine alone, we haven’t solved the crisis of innovation—we have simply decided which lives are worth accelerating.
It is time for the FDA and CMS to recognize that the future of medicine is not one-size-fits-all. Our children deserve a pathway that is just as fast, just as predictable, and just as prioritized as the one we have now built for their grandparents. Anything less is a failure of policy, and more importantly, a failure of our responsibility to the next generation.
